Chemokine receptor CXCR2: Physiology regulator and neuroinflammation controller?

Journal of Neuroimmunology

Volumn 246, Issue 1-2, 2012, Pages 1-9

  Veenstra, Mike ^a,b   Ransohoff, Richard M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Brain pathology; Chemokines; CXCR2; Multiple sclerosis; Neutrophil

Indexed keywords

CHEMOKINE RECEPTOR CXCR2;

ALZHEIMER DISEASE; BONE MARROW DISEASE; CARCINOGENESIS; CELL PROLIFERATION; CYTOKINE RELEASE; DESENSITIZATION; DNA SEQUENCE; GENE EXPRESSION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; LIGAND BINDING; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TRAUMATIC BRAIN INJURY;

ANIMALS; BONE MARROW CELLS; HUMANS; INFLAMMATION; NEURONS; NEUTROPHIL INFILTRATION; RECEPTORS, INTERLEUKIN-8B;

EID: 84860138982     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.02.016     Document Type: Review

References (133)

1. Ahuja S.K., Murphy P.M. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 1996, 271:20545-20550.
2. Ahuja S.K., Ozcelik T., Milatovitch A., Francke U., Murphy P.M. Molecular evolution of the human interleukin-8 receptor gene cluster. Nat. Genet. 1992, 2:31-36.
3. Allen S.J., Crown S.E., Handel T.M. Chemokine: receptor structure, interactions, and antagonism. Annu. Rev. Immunol. 2007, 25:787-820.
4. Amiri K.I., Ha H.C., Smulson M.E., Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene 2006, 25:7714-7722.
5. Anisowicz A., Bardwell L., Sager R. Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:7188-7192.
6. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 1989, 84:1045-1049.
7. Baggiolini M., Loetscher P., Moser B. Interleukin-8 and the chemokine family. Int. J. Immunopharmacol. 1995, 17:103-108.
8. Bai F., Kong K.F., Dai J., Qian F., Zhang L., Brown C.R., Fikrig E., Montgomery R.R. A paradoxical role for neutrophils in the pathogenesis of West Nile virus. J. Infect. Dis. 2010, 202:1804-1812.
9. Bakshi P., Margenthaler E., Reed J., Crawford F., Mullan M. Depletion of CXCR2 inhibits gamma-secretase activity and amyloid-ß production in a murine model of Alzheimer's disease. Cytokine 2011, 53:163-169.
10. Balentien E., Mufson B.E., Shattuck R.L., Derynck R., Richmond A. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 1991, 6:1115-1124.
11. Baugher P.J., Richmond A. The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. J. Biol. Chem. 2008, 283:30868-30878.
12. Bhaskar K., Konerth M., Kokiko-Cochran O.N., Cardona A., Ransohoff R.M., Lamb B.T. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010, 68:19-31.
13. Bielecki B., Mazurek A., Wolinski P., Glabinski A. Treatment of multiple sclerosis with methylprednisolone and mitoxantrone modulates the expression of CXC chemokine receptors in PBMC. J. Clin. Immunol. 2008, 28:122-130.
14. Bordoni R., Thomas G., Richmond A. Growth factor modulation of melanoma growth stimulatory activity mRNA expression in human malignant melanoma cells correlates with cell growth. J. Cell. Biochem. 1989, 39:421-428.
15. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010, 33:657-670.
16. Bozic C.R., Kolakowski L.F., Gerard N.P., Garcia-Rodriguez C., von Uexkull-Guldenband C., Conklyn M.J., Breslow R., Showell H.J., Gerard C. Expression and biologic characterization of the murine chemokine KC. J. Immunol. 1995, 154:6048-6057.
17. Cacalano G., Lee J., Kikly K., Ryan A.M., Pitts-Meek S., Hultgren B., Wood W.I., Moore M.W. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994, 265:682-684.
18. Cardona A.E., Li M., Liu L., Savarin C., Ransohoff R.M. Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol. 2008, 84:587-594.
19. Cardona A.E., Sasse M.E., Liu L., Cardona S.M., Mizutani M., Savarin C., Hu T., Ransohoff R.M. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 2008, 112:256-263.
20. Carlson T., Kroenke M., Rao P., Lane T.E., Segal B. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J. Exp. Med. 2008, 205:811-823.
21. Catusse J., Faye P., Loillier B., Cremers B., Franck R.M., Luccarini J.M., Pruneau D., Paquet J.L. Cloning and characterization of guinea pig interleukin-8 receptor. Biochem. Pharmacol. 2003, 66:1171-1180.
22. Chabas D., Ness J., Belman A., Yeh E.A., Kuntz N., Gorman M.P., Strober J.B., De Kouchkovsky I., McCulloch C., Chitnis T., Rodriguez M., Weinstock-Guttman B., Krupp L.B., Waubant E. Younger children with MS have a distinct CSF inflammatory profile at disease onset. Neurology 2011, 74:399-405.
23. Chapman R.W., Phillips J.E., Hipkin R.W., Curran A.K., Lundell D., Fine J.S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol. Ther. 2009, 121:55-68.
24. Charo I.F., Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 2006, 354:610-621.
25. Cho S.H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer's disease. J. Biol. Chem. 2011, 286:32713-32722.
26. Choi S.H., Veeraraghavalu K., Lazarov O., Marler S., Ransohoff R.M., Ramirez J.M., Sisodia S.S. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 2008, 59:568-580.
27. Coelho F.M., Pinho V., Amaral F.A., Sachs D., Costa V.V., Rodrigues D.H., Vieira A.T., Silva T.A., Souza D.G., Bertini R., Teixeira A.L., Teixeira M.M. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature. Arthritis Rheum. 2008, 58:2329-2337.
28. Craig-Schapiro R., Kuhn M., Xiong C., Pickering E.H., Liu J., Misko T.P., Perrin R.J., Bales K.R., Soares H., Fagan A.M., Holtzman D.M. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLos One 2011, 6:e18850.
29. Crump M.P., Gong J.H., Loetscher P., Rajarathnam K., Amara A., Arenzana-Seisdedos F., Virelizier J.L., Baggiolini M., Sykes B.D., Clark-Lewis I. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997, 16:6996-7007.
30. de Jong B., Kremer B.P., Olde Rikkert M.G., Verbeek M.M. Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin. Chem. Lab. Med. 2007, 45:1421-1434.
31. de Kruijf P., Lim H.D., Roumen L., Renjaän V.A., Zhao J., Webb M.L., Auld D.S., Wijkmans J.C., Zaman G.J., Smit M.J., de Graaf C., Leurs R. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. Mol. Pharmacol. 2011, 80:1108-1118.
32. Dunstan C.A., Salafranca M.N., Adhikari S., Xia Y., Feng L., Harrison J.K. Identification of two rat genes orthologous to the human interleukin-8 receptors. J. Biol. Chem. 1996, 271:32770-32776.
33. Eash K.J., Greenbaum A.M., Gopalan P.K., Link D.C. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J. Clin. Invest. 2010, 120:2423-2431.
34. Fan G.H., Lapierre L.A., Goldenring J.R., Richmond A. Differential regulation of CXCR2 trafficking by Rab GTPases. Blood 2003, 101:2115-2124.
35. Fan X., Patera A.C., Pong-Kennedy A., Deno G., Gonsiorek W., Manfra D.J., Vassileva G., Zeng M., Jackson C., Sullivan L., Sharif-Rodriguez W., Opdenakker G., Van Damme J., Hendrick J.A., Lundell D., Lira S.A., Hipkin R.W. Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J. Biol. Chem. 2007, 282:11658-11666.
36. Frisardi V., Solfrizzi V., Imbimbo P.B., Capurso C., D'Introno A., Colacicco A.M., Vendemiale G., Seripa D., Pilotto A., Capurso A., Panza F. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr. Alzheimer Res. 2010, 7:40-55.
37. Fuhrmann M., Bittner T., Jung C.K., Burgold S., Page R.M., Mitteregger G., Haass C., LaFerla F.M., Kretzschmar H., Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat. Neurosci. 2010, 13:411-413.
38. Furze R.C., Rankin S.M. Neutrophil mobilization and clearance in the bone marrow. Immunology 2008, 125:281-288.
39. Garin A., Proudfoot A.E. Chemokines as targets for therapy. Exp. Cell Res. 2011, 317:602-612.
40. Glabinski A.R., Tani M., Strieter R.M., Tuohy V.K., Ransohoff R.M. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am. J. Pathol. 1997, 150:617-630.
41. Glabinski A.R., Tuohy V.K., Ransohoff R.M. Expression of chemokines RANTES, MIP-1alpha and GRO-alpha correlates with inflammation in acute experimental autoimmune encephalomyelitis. Neuroimmunomodulation 1998, 5:166-171.
42. Greenbaum A.M., Link D.C. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia 2011, 25:211-217.
43. Haskill S., Peace A., Morris J., Sporn S.A., Anisowicz A., Lee S.W., Smith T., Martin G., Sager R. Identification of three related human GRO genes encoding cytokine functions. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:7732-7736.
44. Hayakata T., Shiozaki T., Tasaki O., Ikegawa H., Inoue Y., Toshiyuki F., Hosotubo H., Kieko F., Yamashita T., Tanaka H., Shimazu T., Sugimoto H. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock 2004, 22:102-107.
45. Hebert C.A., Chuntharapai A., Smith M., Colby T., Kim J., Horuk R. Partial functional mapping of the human interleukin-8 type A receptor. Identification of a major ligand binding domain. J. Biol. Chem. 1993, 268:18549-18553.
46. Hipkin R.W., Deno G., Fine J., Sun Y., Wilburn B., Fan X., Gonsiorek W., Wiekowski M.T. Cloning and pharmacological characterization of CXCR1 and CXCR2 from Macaca fascicularis. J. Pharmacol. Exp. Ther. 2004, 310:291-300.
47. Hollman D.W., Klein R.S., Ransohoff R.M. The blood-brain-barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:220-230.
48. Holmes W.E., Lee J., Kuang W.J., Rice G.C., Wood W.I. Structure and functional expression of a human interleukin-8 receptor. Science 1991, 253:1278-1280.
49. Horton L.W., Yu Y., Zaja-Milatovic S., Strieter R.M., Richmond A. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res. 2007, 67:9791-9799.
50. Hosking M.P., Liu L., Ransohoff R.M., Lane T.E. A protective role for ELR+ chemokines during acute viral encephalomyelitis. PLoS Pathog. 2009, 5.
51. Hu Y., Liang D., Li X., Liu H.H., Zhang X., Zheng M., Dill D., Shi X., Qiao Y., Yeomans D., Carvalho B., Angst M.S., Clark J.D., Peltz G. The role of interleukin-1 in wound biology. Part I: murine in silico and in vitro experimental analysis. Anesth. Analg. 2010, 111:1525-1533.
52. Hu Y., Liang D., Li X., Liu H.H., Zhang X., Zheng M., Dill D., Shi X., Qiao Y., Yeomans D., Carvalho B., Angst M.S., Clark J.D., Peltz G. The role of interleukin-1 in wound biology. Part II: in vivo and human translational studies. Anesth. Analg. 2010, 111:1534-1542.
53. Huber A.R., Kunkel S.L., Todd R.F., Weiss S.J. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991, 254:99-102.
54. Huising M.O., Stolte E., Flik G., Savelkoul H.F., Verburg-van Kemenade B.M. CXC chemokines and leukocyte chemotaxis in common carp (Cyprinus carpio L.). Dev. Comp. Immunol. 2003, 27:875-888.
55. Huising M.O., Stet R.J., Kruiswijk C.P., Savelkoul H.F., Verburg-van Kemenade B.M. Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol. 2003, 24:307-313.
56. Kerns H.M., Jutila M.A., Hedges J.F. The distinct response of gammadelta T cells to the Nod2 agonist muramyl dipeptide. Cell. Immunol. 2009, 257:38-43.
57. Kerstetter A.E., Padovani-Claudio D.A., Bai L., Miller R.H. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis. Exp. Neurol. 2009, 220:44-56.
58. Knall C., Young S., Nick J.A., Buhl A.M., Worthen G.S., Johnson G.L. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J. Biol. Chem. 1996, 271:2832-2838.
59. Köhler A., De Fillipo K., Hasenberg M., van den Brandt C., Nye E., Hosking M.P., Lane T.E., Männ L., Ransohoff R.M., Hauser A.E., Winter O., Schraven B., Geiger H., Hogg N., Gunzer M. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood 2011, 117:4349-4357.
60. Kossmann T., Stahel P.F., Lenzlinger P.M., Redl H., Dubs R.W., Trentz O., Schlag G., Morganti-Kossmann M.C. Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J. Cereb. Blood Flow Metab. 1997, 17:280-289.
61. Kraemer S., Lue H., Zernecke A., Kapurniotu A., Andreetto E., Frank R., Lennartz B., Weber C., Bernhagen J. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J. 2011, 25:894-906.
62. Krieger M., Brunner T., Bischoff S.C., von Tscharner V., Walz A., Moser B., Baggiolini M., Dahinden C.A. Activation of human basophils through the IL-8 receptor. J. Immunol. 1992, 149:2662-2667.
63. Lazanecc G., Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 2010, 16:133-144.
64. Lee J., Horuk R., Richard Y., Bennet G.L., Camerato T., Wood W.I. Characterization of two high affinity human interleukin-8 receptors. J. Biol. Chem. 1992, 267:16283-16287.
65. Lee S., Varvel N.H., Konerth M.E., Xu G., Cardona A.E., Ransohoff R.M., Lamb B.T. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 2010, 177:2549-2562.
66. Ley K., Smith E., Stark M.A. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol. Res. 2006, 34:229-242.
67. Lindner M., Trebst C., Heine S., Skripuletz T., Koutsoudaki P.N., Stangel M. The chemokine receptor CXCR2 is differentially regulated on glial cells in vivo but is not required for successful remyelination after cuprizone-induced demyelination. Glia 2008, 56:1104-1113. erratum, 57, 465 (2009).
68. Lippert U., Zachmann K., Henz B.M., Neumann C. Human T lymphocytes and mast cells differentially express and regulate extra- and intracellular CXCR1 and CXCR2. Exp. Dermatol. 2004, 13:520-525.
69. Liu L., Belkaldi A., Darnall L., Hu T., Drescher C., Cotleur A.C., Padovani-Claudio D., He T., Choi K., Lane T.E., Miller R.H., Ransohoff R.M. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat. Neurosci. 2010, 13:319-326.
70. Liu L., Darnall L., Hu T., Choi K., Lane T.E., Ransohoff R.M. Myelin repair is accelerated by inactivating CXCR2 on nonhematopoietic cells. J. Neurosci. 2010, 30:9074-9083.
71. Lodowski D.T., Palczewski K. Chemokine receptors and other G protein-coupled receptors. Curr. Opin. HIV AIDS 2009, 4:88-95.
72. Lund B.T., Ashikian N., Ta H.Q., Chakryan Y., Manoukian K., Groshen S., Gilmore W., Cheema G.S., Stohl W., Burnett M.E., Ko D., Kachuck N.J., Weiner L.P. Increased CXCL8 (IL-8) expression in multiple sclerosis. J. Neuroimmunol. 2004, 155:161-171.
73. Maier B., Schwerdtfeger K., Mautes A., Holanda M., Müller M., Steudel W.I., Marzi I. Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock 2001, 15:421-426.
74. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 2009, 284:6038-6042.
75. McColl S.R., Staykova M.A., Wozniak A., Fordham S., Bruce J., Willenborg D.O. Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 1998, 161:6421-6426.
76. McDonald B., Pittman K., Menezes G.B., Hirota S.A., Slaba I., Waterhouse C.C., Beck P.L., Muruve D.A., Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366.
77. Monteclaro F.S., Charo I.F. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. 1996, 271:19084-19092.
78. Moser B., Schumacher C., von Tscharner V., Clark-Lewis I., Baggiolini M. Neutrophil-activating peptide 2 and gro/melanoma growth-stimulatory activity interact with neutrophil-activating peptide 1/interleukin 8 receptors on human neutrophils. J. Biol. Chem. 1991, 266:10666-10671.
79. Murdoch C., Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000, 95:3032-3043.
80. Murphy P.M., Tiffany H.L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991, 253:1280-1283.
81. Murphy P.M., Charo I.F., Hills R., Horuk R., Matsushima K., Oppenheim J.J. Chemokine receptors 2011, pp. Accessed on 2011-08-23-IUPHAR database (IUPHAR-DB). http://www.iuphar-db.org/DATABASE/FamilyMenuForward?familyId=14.
82. Nasser M.W., Raghuwanshi S.K., Malloy K.M., Gangavarapu P., Shim J.Y., Rajarathnam K., Richardson R.M. CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization. J. Biol. Chem. 2007, 282:6906-6915.
83. Neel N.F., Schutyser E., Sai J., Fan G.H., Richmond A. Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev. 2005, 16:637-658.
84. Netea M.G., van de Veerdonk F.L., Kullberg B.J., Van der Meer J.W., Joosten L.A. The role of NLRs and TLRs in the activation of the inflammasome. Expert. Opin. Biol. Ther. 2008, 8:1867-1872.
85. Oh J.W., Schwiebert L.M., Benveniste E.N. Cytokine regulation of CC and CXC chemokine expression by human astrocytes. J. Neurovirol. 1999, 5:82-94.
86. Omari K.M., John G., Lango R., Raine C.S. Role for CXCR2 and CXCL1 on glia in multiple sclerosis. Glia 2006, 53:24-31.
87. Omari K.M., Lutz S.E., Santambrogio L., Lira S.A., Raine C.S. Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1. Am. J. Pathol. 2009, 174:164-176.
88. Padovani-Claudio D.A., Liu L.P., Ransohoff R.M., Miller R.H. Alterations in the oligodendrocyte lineage, myelin and white matter in adult mice lacking the chemokine receptor CXCR2. Glia 2006, 54:471-483.
89. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Le Trong I., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289:739-745.
90. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., Ponomaryov T., Taichman R.S., Arenzana-Seisdedos F., Fujii N., Sandbank J., Zipori D., Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 2002, 3:687-694.
91. Pighetti G.M., Rambeaud M. Genome conservation between the bovine and human interleukin-8 receptor complex: improper annotation of bovine interleukin-8 receptor b identified. Vet. Immunol. Immunopathol. 2006, 114:335-340.
92. Prado G.N., Thomas K.M., Suzuki H., LaRosa G.J., Wilkinson N., Folco E., Navarro J. Molecular characterization of a novel rabbit interleukin-8 receptor isotype. J. Biol. Chem. 1994, 269:12391-12394.
93. Prado G.N., Suetomi K., Shumate D., Maxwell C., Ravindran A., Rajarathnam K., Navarro J. Chemokine signaling specificity: essential role for the N-terminal domain of chemokine receptors. Biochemistry 2007, 46:8961-8968.
94. Proost P., De Wolf-Peeters C., Conings R., Opdenakker G., Billiau A., Van Damme J. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J. Immunol. 1993, 150:1000-1010.
95. Provencio J.J., Altay T., Smithason S., Moore S.K., Ransohoff R.M. Depletion of Ly6G/C(+) cells ameliorates delayed cerebral vasospasm in subarachnoid hemorrhage. J. Neuroimmunol. 2011, 232:94-100.
96. Rajagopalan L., Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J. Biol. Chem. 2004, 279:30000-30008.
97. Rajagopalan L., Rajarathnam K. Structural basis of chemokine receptor function - a model for binding affinity and ligand selectivity. Biosci. Rep. 2006, 26:325-339.
98. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007, 256:137-165.
99. Raman D., Neel N.F., Sai J., Mernaugh R.L., Ham A.J., Richmond A.J. Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Methods Enzymol. 2009, 460:315-330.
100. Raman D., Sobolik-Delmaire T., Richmond A. Chemokines in health and disease. Exp. Cell Res. 2011, 317:575-589.
101. Ramos C.D., Fernandes K.S., Canetti C., Teixeira M.M., Silva J.S., Cunha F.Q. Neutrophil recruitment in immunized mice depends on MIP-2 inducing the sequential release of MIP-1alpha, TNF-alpha and LTB(4). Eur. J. Immunol. 2006, 36:2025-2034.
102. Ransohoff R.M. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009, 31:711-721.
103. Ransohoff R.M., Liu L., Cardona A.E. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. Int. Rev. Neurobiol. 2007, 82:187-204.
104. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
105. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
106. Rhodes S.J., Sharkey J., Andrews P. Serum IL-8 and MCP-1 concentration do not identify patients with enlarging contusions after traumatic brain injury. J. Trauma 2009, 66:1591-1597.
107. Richmond A., Lawson D.H., Nixon D.W., Stevens J.S., Chawla R.K. Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs0294 human melanoma cell line. Cancer Res. 1983, 43:2106-2112.
108. Richmond A., Lawson M.A., Nixon D.W., Chawla R.K. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res. 1985, 45:6390-6394.
109. Richmond A., Balentien E., Thomas H.G., Flaggs G., Barton D.E., Spiess J., Bordoni R., Francke U., Derynck R. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J. 1988, 7:2025-2033.
110. Robinson S., Tani M., Strieter R.M., Ransohoff R.M., Miller R.H. The chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte precursor proliferation. J. Neurosci. 1998, 18:10457-10463.
111. Robinson S., Cohen M., Prayson R., Ransohoff R.M., Tabrizi N., Miller R.H. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery 2001, 48:864-873.
112. Salanga C.L., Handel T.M. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 2011, 317:590-601.
113. Savarin-Vuaillat C., Ransohoff R.M. Chemokines and chemokine receptors in neurological disease: raise, retain or reduce?. Neurotherapeutics 2007, 4:590-601.
114. Schwartz M., Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:405-410.
115. Semple B.D., Bye N., Ziebell J.M., Morganti-Kossmann M.C. Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. Neurobiol. Dis. 2010, 40:394-403.
116. Singh S., Sing A.P., Sharma B., Owen L.B., Singh R.K. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol. 2010, 6:111-116.
117. Tani M., Fuentes M.E., Peterson J.W., Trapp B.D., Durham S.K., Loy J.K., Bravo R., Ransohoff R.M., Lira S.A. Neutrophil infiltration, glial reaction, and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J. Clin. Invest. 1996, 98:529-539.
118. Tirotta E., Ransohoff R.M., Lane T.E. CXCR2 signaling protects oligodendrocyte progenitor cells from IFN-?/CXCL10-mediated apoptosis. Glia 2011, 59:1518-1528.
119. Tsai H.H., Frost E., To V., Robinson S., French-Constant C., Geertman R., Ransohoff R.M., Miller R.H. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110:373-383.
120. Vallès A., Grijpink-Ongering L., de Bree F.M., Tuinstra T., Ronken E. Differential regulation of the CXCR2 chemokine network in rat brain trauma: implications for neuroimmune interactions and neuronal survival. Neurobiol. Dis. 2006, 22:312-322.
121. van de Veerdonk F.L., Netea M.G., Dinarello C.A., Joosten L.A. Inflammasome activation and IL-1beta and IL-18 processing during infection. Trends Immunol. 2011, 32:110-116.
122. Vasilescu A., Terashima Y., Enomoto M., Heath S., Poonpiriya V., Gatanaga H., Do H., Diop G., Hirtzig T., Auewarakul P., Lauhakirti D., Sura T., Charneau P., Marullo S., Therwath A., Oka S., Kanegasaki S., Lathrop M., Matsushima K., Zagury J.F., Matsuda F. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3354-3359.
123. Vieira S.M., Lemos H.P., Grespan R., Napimoga M.H., Dal-Secco D., Freitas A., Cunha T.M., Verri W.A., Souza-Junior D.A., Jamur M.C., Fernandes K.S., Oliver C., Silva J.S., Teixeira M.M., Cunha F.Q. A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br. J. Pharmacol. 2009, 158:779-789.
124. Walz A., Burgener R., Car B., Baggiolini M., Kunkel S.L., Strieter R.M. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med. 1991, 174:1355-1362.
125. Weiner H.L. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 2009, 65:239-248.
126. Wengner A.M., Pitchford S.C., Furze R.C., Rankin S.M. The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation. Blood 2008, 111:42-49.
127. Whalen M.J., Carlos T.M., Kochanek P.M., Wisniewski S.R., Bell M.J., Clark R.S., DeKosky S.T., Marion D.W., Adelson P.D. Interleukin-8 is increased in cerebrospinal fluid of children with severe head injury. Crit. Care Med. 2000, 28:929-934.
128. Wu J.Y., Feng L., Park H.T., Havlioglu N., Wen L., Tang H., Bacon K.B., Jiang Zh., Zhang Xc, Rao Y. The neuronal repellent Slit inhibits leukocyte chemotaxis induced by chemotactic factors. Nature 2001, 410:948-952.
129. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R., Brooun A., Wells P., Bi F.C., Hamel D.J., Handel T.M., Cherezov V., Steven R.C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists 2010.
130. Xia M., Hyman B.T. GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation-a role in Alzheimer's disease?. J. Neuroimmunol. 2002, 122:55-64.
131. Yoshimura T., Matsushima K., Tanaka S., Robinson E.A., Appella E., Oppenheim J.J., Leonard E.J. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide similarity to other host defense cytokines. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:9233-9237.
132. Zaja-Milatovic S., Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol. Histopathol. 2008, 23:1399-1407.
133. Zhang J., Sokal I., Peskind A.R., Quinn J.F., Jankovic J., Kenney C., Chung K.A., Millard S.P., Nutt J.G., Montine T.J. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 2008, 129:526-529.